secwatch.observer — SEC 8-K summary
======================================

Issuer:     Senti Biosciences, Inc. (SNTI)
CIK:        0001854270
Form:       8-K
Filed at:   2024-12-16T23:59:59+00:00
Accession:  0001854270-24-000128
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Senti Bio doses first patient in SN301A CAR-NK trial for liver cancer in China
------------------------------------------------------------------------------

- First patient dosed in SN301A pilot trial for advanced GPC3-expressing HCC in mainland China.
- SN301A is SENTI-301A CAR-NK product candidate manufactured and developed by Celest Therapeutics.
- Open-label, single-center study (NCT06652243) evaluating safety, pharmacokinetics, and anti-tumor activity.
- Three dose levels administered in 28-day cycles with lymphodepletion conditioning.
- Over 40% of global HCC cases occur in China; Senti retains rights outside Greater China.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1854270/000185427024000128/0001854270-24-000128-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1854270/000185427024000128/snti-20241216.htm
  HTML page:      https://secwatch.observer/filing/0001854270-24-000128

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer